Adma Biologics (ADMA) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $0.17.
- Adma Biologics' Debt to Equity fell 6155.83% to $0.17 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.17, marking a year-over-year decrease of 6155.83%. This contributed to the annual value of $0.21 for FY2024, which is 7854.22% down from last year.
- According to the latest figures from Q3 2025, Adma Biologics' Debt to Equity is $0.17, which was down 6155.83% from $0.18 recorded in Q2 2025.
- Adma Biologics' 5-year Debt to Equity high stood at $1.41 for Q3 2022, and its period low was $0.17 during Q3 2025.
- Over the past 5 years, Adma Biologics' median Debt to Equity value was $0.85 (recorded in 2024), while the average stood at $0.76.
- As far as peak fluctuations go, Adma Biologics' Debt to Equity surged by 5338.57% in 2022, and later crashed by 7854.22% in 2024.
- Over the past 5 years, Adma Biologics' Debt to Equity (Quarter) stood at $0.67 in 2021, then surged by 39.86% to $0.94 in 2022, then rose by 2.77% to $0.97 in 2023, then tumbled by 78.54% to $0.21 in 2024, then fell by 18.95% to $0.17 in 2025.
- Its Debt to Equity stands at $0.17 for Q3 2025, versus $0.18 for Q2 2025 and $0.19 for Q1 2025.